Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | JAK2 V617F |
| Therapy | Crizotinib |
| Indication/Tumor Type | myeloproliferative neoplasm |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| JAK2 V617F | myeloproliferative neoplasm | sensitive | Crizotinib | Preclinical | Actionable | In a preclinical study, Xalkori (crizotinib) treatment resulted in reduced spleen weights in a myeloproliferative neoplasm knock-in mouse model expressing JAK2 V617F (PMID: 36537918). | 36537918 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (36537918) | Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. | Full reference... |